
LQDA Stock Forecast & Price Target
LQDA Analyst Ratings
Bulls say
Liquidia is positioned for success in the biopharmaceutical industry with its unique PRINT technology, which has the potential to improve drug delivery to the lungs. The company's lead product candidate, Yutrepia, has shown strong performance in clinical trials and has the potential to become the best-in-class inhaled treprostinil treatment for pulmonary hypertension. Additionally, the company's upcoming study plans and development of L606 for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD) further support its growth potential. However, legal challenges to Yutrepia's freedom to operate and competition within the market remain risks to consider.
Bears say
Liquidia is a biopharmaceutical company that develops and manufactures drugs for pulmonary hypertension (PH) and interstitial lung disease (ILD). While the recently completed 24-week ASCENT study showed positive results for its inhaled treprostinil product, Yutrepia, there is still a lack of robust studies supporting its use in PH-ILD. Furthermore, the ongoing legal challenges to Yutrepia's freedom to operate could significantly impair Liquidia's ability to launch and sell its product, leading to potential financial penalties. These risks, combined with United Therapeutics' established position in the market and potential legal threats, make for a negative outlook on Liquidia's stock.
This aggregate rating is based on analysts' research of Liquidia Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.
LQDA Analyst Forecast & Price Prediction
Start investing in LQDA
Order type
Buy in
Order amount
Est. shares
0 shares